The present work was undertaken with two main goals: 1) to further elucidate the physiological role of the adenosine 3',5'-cyclic monophosphate (cAMP) and Ca2(+)-calmodulin (Ca2(+)-Cm)-dependent mechanisms of phospholamban phosphorylation (32PiPHL), and 2) to study the possible interaction between these two systems in the intact heart. Interventions that increased twitch or tetanic tension without modifying cAMP levels [high extracellular Ca2+ concentration [( Ca2+]o) or BAY K 8644 in catecholamine-depleted hearts] failed to alter 32PiPHL. Moderate and high beta-adrenergic stimulation (3 x 10(-9) and 3 x 10(-8) M isoproterenol, respectively) increased cAMP from 0.345 +/- 0.032 to 0.636 +/- 0.069 and 0.772 +/- 0.060 pmol/mg wet wt, and 32PiPHL from 26.8 +/- 4.1 to 58.6 +/- 13.1 and 174.7 +/- 13.8 pmol 32Pi/mg sarcoplasmic reticular [SR] protein, respectively. Both doses of isoproterenol produced an enhanced myocardial relaxation. Reversal of the positive inotropic effect of isoproterenol by interventions that decrease intracellular Ca2+ supply failed to reduce the enhancement in 32PiPHL and myocardial relaxation elicited by 3 x 10(-9) M isoproterenol but diminished the increase in 32PiPHL induced by 3 x 10(-8) M isoproterenol to 116.3 +/- 10.9 without significant changes in cAMP. Changes in myocardial relaxation closely paralleled the changes in 32PiPHL. These results suggest that 1) 32PiPHL may be enhanced by the cAMP-dependent mechanism independently of the Ca2(+)-Cm system, and 2) 32PiPHL and myocardial relaxation may be modified by intracellular Ca2+ changes only at high-intracellular cAMP levels.
The role of the Ca(2+)-calmodulin dependent pathway of phospholamban phosphorylation on the relaxant effect of beta-adrenergic agonists was studied in isolated perfused rat heart. Administration of the calmodulin antagonist W7 or lowering [Ca]o from 1.35 mM (control) to 0.25 mM, were used as experimental tools to inhibit the Ca(2+)-calmodulin dependent protein kinase activity. 3 x 10(-8) M isoproterenol increased cAMP levels from 0.613 +/- 0.109 pmol/mg wet weight to 1.581 +/- 0.123, phospholamban phosphorylation from 36 +/- 6 pmol 32P/mg protein to 277 +/- 26 and decreased time to half relaxation (t1/2) from 61 +/- 2 msec to 39 +/- 2. Simultaneous perfusion of isoproterenol with 10(-6) M W7, decreased phospholamban phosphorylation to 170 +/- 23 and prolongated t1/2 to 47 +/- 3 but did not affect the increase either in cAMP levels or myocardial contractility produced by isoproterenol. Similar effects on phospholamban phosphorylation and myocardial relaxation were obtained when isoproterenol was perfused in low [Ca]o. Low [Ca]o did not affect the increase in cAMP elicited by isoproterenol but offset the positive inotropic effect of the beta-agonist. The results suggest a physiological role of the Ca(2+)-calmodulin dependent phospholamban phosphorylation pathway as a mechanism that supports, in part, the beta-adrenergic cardiac relaxant effect.
The effect of beta-adrenergic stimulation on tetanic tension (TT), maximal rate of rise of tension (+TT) and phospholamban (PHL) phosphorylation were studied in the perfused rat heart. 3 x 10(-8) M isoproterenol perfused at different [Ca2+]o 0.25, 1.35 and 3.85 mM, significantly decreased TT while increased +TT and PHL phosphorylation at the three [Ca2+]o studied. Regression lines of the relationship between +TT and TT from individual data obtained at each [Ca2+]o in the presence and in the absence of isoproterenol, show that for the same level of +TT, TT is lower in the presence of isoproterenol, i.e. at high levels of PHL phosphorylation. The slopes of the lines were 0.137 s and 0.427 s (P less than 0.05) in the presence and absence of isoproterenol respectively. The decrease in TT produced by the beta-agonist can be attributed to its relaxant action prevailing over its inotropic effect and may represent the mechanical expression of the enhanced phosphorylation of phospholamban.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.